Article
Gastroenterology & Hepatology
Tatyana Kushner, Nancy Reau
Summary: Despite significant advancements in HCV treatment with direct-acting antivirals, HCV remains a global public health concern, especially with the increasing prevalence in women of childbearing age. Active HCV during pregnancy is associated with cholestasis of pregnancy and the risk of mother-to-child transmission, prompting guidelines to recommend universal screening during pregnancy and ongoing research in the treatment of HCV during pregnancy.
JOURNAL OF HEPATOLOGY
(2021)
Article
Medicine, General & Internal
Hsu-Heng Yen, Yang-Yuan Chen, Jun-Hung Lai, Hung-Ming Chen, Chih-Ta Yao, Siou-Ping Huang, I-Ling Liu, Ya-Huei Zeng, Fang-Chi Yang, Fu-Yuan Siao, Mei-Wen Chen, Pei-Yuan Su
Summary: This study evaluated the real-world safety and efficacy of two pan-genotypic regimens for HCV-infected patients with mixed or undetermined HCV genotypes. The results showed that both regimens were effective and well-tolerated for these patients in real-world settings.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Xiaomi Li, Jingyan Wang, Xiaoyan Ding, Yawen Xu, Minghua Yu, Hongxiao Wu, Na Deng, Wei Li, Jinglong Chen
Summary: The clinical efficacy of lenvatinib was compared between hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and hepatitis C virus (HCV)-related HCC. The study found that patients with HBV-HCC had higher objective response rate and disease control rate compared to HCV-HCC, but there were no significant differences in progression-free survival and overall survival between the two groups. Multivariate regression analysis identified HBV infection and antiviral time > 5 years as independent favorable factors for progression-free survival. Overall, lenvatinib seemed to be more effective in HBV-related HCC compared to HCV-related HCC.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Gastroenterology & Hepatology
Ewa Janczewska, Mateusz Franciszek Kolek, Beata Lorenc, Jakub Klapaczynski, Magdalena Tudrujek-Zdunek, Marek Sitko, Wlodzimierz Mazur, Dorota Zarebska-Michaluk, Iwona Buczynska, Dorota Dybowska, Agnieszka Czau-Anderzejuk, Hanna Berak, Rafal Krygier, Jerzy Jaroszewicz, Jolanta Citko, Anna Piekarska, Beata Dobracka, Lukasz Socha, Zbigniew Deron, Lukasz Laurans, Jolanta Bialkowska-Warzecha, Olga Tronina, Brygida Adamek, Krzysztof Tomasiewicz, Krzysztof Simon, Malgorzata Pawlowska, Waldemar Halota, Robert Flisiak
Summary: This study analyzed factors influencing the failure of direct-acting antiviral drugs in a real-world setting, including liver function status, viral factors, and gender.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Obstetrics & Gynecology
Sarah K. Dotters-Katz, Jeffrey A. Kuller, Brenna L. Hughes
Summary: In the United States, 1% to 4% of pregnant women are estimated to be infected with hepatitis C virus, which poses a 5% risk of transmission to infants. Regular screenings and early viral hepatitis testing for pregnant women with intrahepatic cholestasis of pregnancy are recommended to manage the risks associated with hepatitis C virus during pregnancy.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2021)
Article
Medicine, General & Internal
Man-Fung Yuen, Seng-Gee Lim, Robert Plesniak, Keiji Tsuji, Harry L. A. Janssen, Cristina Pojoga, Adrian Gadano, Corneliu P. Popescu, Tatyana Stepanova, Tarik Asselah, Gheorghe Diaconescu, Hyung Joon Yim, Jeong Heo, Ewa Janczewska, Alexander Wong, Nevin Idriz, Michio Imamura, Giuliano Rizzardini, Koichi Takaguchi, Pietro Andreone, Manuela Arbune, Jinlin Hou, Sung Jae Park, Andrei Vata, Jennifer Cremer, Robert Elston, Tamara Lukic, Geoff Quinn, Lauren Maynard, Stuart Kendrick, Helene Plein, Fiona Campbell, Melanie Paff, Dickens Theodore, B-Clear Study Grp
Summary: Bepirovirsen treatment for 24 weeks at a dose of 300 mg per week resulted in sustained loss of hepatitis B surface antigen (HBsAg) and HBV DNA in 9%-10% of patients with chronic HBV infection. Larger and longer trials are needed to assess the efficacy and safety of bepirovirsen.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Jordan J. Feld, Anna S. Lok, Fabien Zoulim
Summary: Current therapy for chronic hepatitis B rarely achieves a functional cure, but novel treatments are being developed. Understanding the mechanisms of hepatitis B virus persistence has helped identify new treatment targets and evaluate novel agents in clinical trials. Combining different agents appears to be a promising strategy to reduce viral replication, invigorate immune responses, and induce specific adaptive immune responses.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Samuel Anthony Lachlan Hall, Sara Vogrin, Olivia Wawryk, Gareth S. Burns, Kumar Visvanathan, Vijaya Sundararajan, Alexander Thompson
Summary: A meta-analysis was conducted on clinical outcomes after nucleot(s)ide analogue (NA) discontinuation for HBeAg-negative CHB patients, revealing that virological relapse is common but clinical relapse occurs in only one-third of patients at 12 months post-NA discontinuation. Discontinuation of NA therapy can lead to HBsAg clearance, with higher rates observed with longer follow-up periods.
Review
Gastroenterology & Hepatology
Wen-Juei Jeng, Anna S. Lok
Summary: Current treatment for chronic hepatitis B virus (HBV) does not eradicate the virus, requiring long-term maintenance for most patients. Expanding treatment to certain patient populations, such as immune tolerant patients and those with evidence of liver disease, is supported by available evidence. However, data supporting treatment expansion for confirmed inactive carriers and other immune tolerant patients is lacking. New therapies that can achieve HBsAg loss in a high percentage of patients after a finite course of treatment may allow for more liberal HBV treatment indications in the future.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Review
Gastroenterology & Hepatology
Sun Woong Kim, Jun Sik Yoon, Minjong Lee, Yuri Cho
Summary: Hepatitis B virus (HBV) infection is a serious global public health problem, and there is currently no complete cure. The focus of recent research has been on achieving a functional cure for HBV through combination therapies and immunomodulators. New therapeutic approaches and clinical trials are being conducted to find a long-lasting cure for HBV infection.
CLINICAL AND MOLECULAR HEPATOLOGY
(2022)
Review
Microbiology
Carla E. Gallardo-Flores, Che C. Colpitts
Summary: Cyclophilins play important roles in HCV infection, with cyclophilin inhibitor therapy showing effectiveness in reducing viral replication. Recently, cyclophilins have also been identified as host factors for flavivirus infection. Further research is needed to clarify the roles of cyclophilins in flavivirus replication.
Article
Gastroenterology & Hepatology
Hye Won Lee, Terry Cheuk-Fung Yip, Yee-Kit Tse, Grace Lai-Hung Wong, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Henry Lik-Yuen Chan, Sang Hoon Ahn, Vincent Wai-Sun Wong
Summary: This study reported the incidence and predictors of hepatic decompensation among cirrhotic patients receiving antiviral therapy for chronic hepatitis B. The results showed that hepatic decompensation is uncommon but not eliminated, with factors such as baseline liver stiffness measurement, diabetes, and blood indicators being associated with decompensation.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Medicine, General & Internal
Gian Paolo Caviglia, Yulia Troshina, Enrico Garro, Marcantonio Gesualdo, Serena Aneli, Giovanni Birolo, Fabrizia Pittaluga, Rossana Cavallo, Giorgio Maria Saracco, Alessia Ciancio
Summary: Quantitative HBsAg is useful in predicting HBsAg seroclearance in Caucasian patients with chronic hepatitis B receiving treatment with antivirals in North-West Italy.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Biology
Busara Songtanin, Kenneth Nugent
Summary: Hepatitis C virus (HCV) is a significant cause of chronic liver diseases worldwide and is associated with negative consequences, including cirrhosis, hepatocellular carcinoma, and increased risk of mortality. In addition to liver-related morbidities, HCV is also associated with several extrahepatic manifestations. Despite the introduction of direct-acting antiviral drugs, a considerable number of patients still develop extrahepatic complications.
Article
Gastroenterology & Hepatology
Philip Vutien, Nicole J. Kim, Andrew M. Moon, Kay M. Johnson, Kristin Berry, Pamela K. Green, George N. Ioannou
Summary: Among cirrhotic patients and those with cured HCV infection, the risk of HCC decreases over time since sustained virologic response (SVR), although it remains above the threshold for screening.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)